Announcements Trials
Browse Landscape

Phase

Phase 2 79Phase 1/2 70Phase 1 69Phase 3 28Phase 2/3 6Phase NA 5Phase 4 3Phase EARLY_PHASE1 1

Status

Recruiting 3Not yet recruiting 2Completed 1

Sponsor Class

INDUSTRY 4OTHER 2

Study Type

Interventional 6

Sponsor

Cancer Type

Gastrointestinal 2Breast 2Other hematologic neoplasm 1NET 1Genitourinary 1Endocrine 1

Conditions

Triple Negative Breast Neoplasms 1Rectal Neoplasms 1Prostatic Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Leukemia, Myeloid, Acute 1Gastroenteropancreatic Neuroendocrine Tumors 1Colorectal Neoplasms 1Breast Neoplasms 1

Interventions

Cisplatin 30Magnetic Resonance Spectroscopy 23Carboplatin 23pembrolizumab 21Paclitaxel 20Gemcitabine 19Specimen Handling 16Drug Therapy 15Dexamethasone 15Radiotherapy 14Nivolumab 14Doxorubicin 14Bevacizumab 14atezolizumab 13Oxaliplatin 13Cyclophosphamide 13Radiation 11Pemetrexed 11Cytarabine 11Vincristine 10Prednisone 10Docetaxel 10Capecitabine 10venetoclax 9Trastuzumab 9Temozolomide 8Rituximab 8Platinum 8Ipilimumab 8Fluorouracil 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 2/3 × Injections × 1 year × Clear all
NCT06788756 2026-04-29

L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML

Moleculin Biotech, Inc.

Phase 2/3 Recruiting
312 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT07165886 2026-04-24

Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Phase 2/3 Recruiting
298 enrolled
EndocrineGastrointestinalNET

Gastroenteropancreatic Neuroendocrine Tumors

NCT07544056 2026-04-22

A Study of BEBT-209 Plus Chemotherapy in Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer

BeBetter Med Inc

Phase 2/3 Not yet recruiting
446 enrolled
Breast

Triple Negative Breast Neoplasms

NCT06282588 2026-03-19

THUNDER

Cancer Research Antwerp

Phase 2/3 Recruiting
493 enrolled
Genitourinary

Prostatic Neoplasms

NCT06009627 2026-02-10

Study of Neoadjuvant Endocrine Therapy in HR Positive and HER2 Negative Premenopausal Breast Cancer Patients

Tianjin Medical University Cancer Institute and Hospital

Phase 2/3 Completed
119 enrolled
Breast

Breast Neoplasms

NCT07321847 2026-01-07

INJECTABL-3

Immunophotonics, Inc.

Phase 2/3 Not yet recruiting
717 enrolled
Gastrointestinal

Neoplasm Metastasis, Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡